1921
Volume 102, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Hydroxychloroquine (HCQ) has been used for the treatment of novel coronavirus disease (COVID-19) cases. However, evidence of efficacy remains limited, and adverse events can be associated with its use. Here, we report a case of a patient with severe COVID-19 who, after being administered HCQ, exhibited a 10-fold increase in serum levels of transaminases, followed by a rapid decrease after HCQ was withdrawn. Considering the significantly increased use of HCQ during the COVID-19 pandemic, this case alerts us to the potential for HCQ to be associated with hepatotoxicity and the need to monitor liver function during HCQ therapy.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.20-0276
2020-04-17
2020-09-28
Loading full text...

Full text loading...

/deliver/fulltext/14761645/102/6/tpmd200276.html?itemId=/content/journals/10.4269/ajtmh.20-0276&mimeType=html&fmt=ahah

References

  1. Ashour HM, Elkhatib WF, Rahman MM, Elshabrawy , 2020. Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks. Pathogens 9: 115.
    [Google Scholar]
  2. Gralinski LE, Menachery VD, 2020. Return of the coronavirus: 2019-nCoV. Viruses 12: 18.
    [Google Scholar]
  3. World Health Organization, 2020. Coronavirus Disease 2019 (COVID-19) Situation Report-78. Geneva, Switzerland: World Health Organization.
    [Google Scholar]
  4. Wu Z, McGoogan JM, 2020. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. [ePub ahead of print 2020 Feb 24]. Available at: https://doi.org/10.1001/jama.2020.2648.
    [Google Scholar]
  5. Mizumoto K, Chowell G, 2020. Estimating risk for death from 2019 novel coronavirus disease, China, January–February 2020. Emerg Infect Dis 26: 19.
    [Google Scholar]
  6. Yao X et al., 2020. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome main point: hydroxychloroquine was found to be more potent than chloroquine at inhibiting SARS-CoV-2 in vit. Clin Infect Dis 2: 125.
    [Google Scholar]
  7. Liu J et al., 2020. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 6: 14.
    [Google Scholar]
  8. Gautret P et al., 2020. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020 Mar 20: 105949. Available at: https://doi:10.1016/j.ijantimicag.2020.105949.
    [Google Scholar]
  9. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S, 2020. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020 Mar 10. pii: S0883-9441(20)30390-7. Available at: https://doi:10.1016/j.jcrc.2020.03.005.
    [Google Scholar]
  10. Liang T, 2020. Handbook of COVID-19 Prevention and Treatment. Available at: https://covid-19.alibabacloud.com.
    [Google Scholar]
  11. Keshtkar-Jahromi M, Bavari S, 2020. A call for randomized controlled trials to test the efficacy of chloroquine and hydroxychloroquine as therapeutics against novel coronavirus disease (COVID-19). Am J Trop Med Hyg 102: 932933.
    [Google Scholar]
  12. Ferner RE, Aronson JK, 2020. Chloroquine and hydroxychloroquine in covid-19. BMJ 2020 Apr 8;369:m1432. Available at: https://doi:10.1136/bmj.m1432.
    [Google Scholar]
  13. Mégarbane B, 2020. Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution. Clin Toxicol (Phila) 2020 Apr 2: 1–2. Available at: https://doi:10.1080/15563650.2020.1748194.
    [Google Scholar]
  14. Mahase E, 2020. Covid-19: six million doses of hydroxychloroquine donated to us despite lack of evidence. BMJ 2020 Mar 23;368:m1166. Available at: https://doi:10.1136/bmj.m1166.
    [Google Scholar]
  15. Argumánez CM, La Fuente ISD, Collado ZM, Pita DS, Gómez BM, Izquierdo JAS, 2017. Hydroxychloroquine, a potentially lethal drug. Med Intensiva 41: 257259.
    [Google Scholar]
  16. Wang D et al., 2020. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323: 10611069.
    [Google Scholar]
  17. Guan W et al., 2020. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020 Feb 28. Available at: https://doi:10.1136/bmj.m1166.
    [Google Scholar]
  18. Huang C et al., 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497506.
    [Google Scholar]
  19. Zhou F et al., 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 6736: 19.
    [Google Scholar]
  20. Chen N et al., 2020. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395: 507513.
    [Google Scholar]
  21. Zhang B et al., 2020. Clinical characteristics of 82 death cases with COVID-19 bicheng. medRxiv 2020.02.26.20028191. Available at: https://doi:10.1017/CBO9781107415324.004.
    [Google Scholar]
  22. Al-Bari AA, 2014. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother 70: 16081621.
    [Google Scholar]
  23. van Jaarsveld CH et al., 2000. Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis. Rheumatology 39: 13741382.
    [Google Scholar]
  24. Sunkara B, Roofeh D, Silver S, Pearson TL, Ettel M, McCune WJ, 2018. The devil’s in the dosing: severe drug-induced liver injury in a hydroxychloroquine-naive patient with subacute cutaneous lupus erythematosus and porphyria cutanea tarda. Lupus 27: 13831386.
    [Google Scholar]
  25. Mok MY, Ng WL, Yuen MF, Wong RWS, Lau CS, 2000. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 18: 363368.
    [Google Scholar]
  26. Wei CH, Penunuri A, Karpouzas G, Fleishman W, Datta A, French SW, 2015. Troxis necrosis, a novel mechanism for drug-induced hepatitis secondary to immunomodulatory therapy. Exp Mol Pathol 99: 341343.
    [Google Scholar]
  27. Makin AJ, Wendon J, Fitt S, Portmann BC, Williams R, 1994. Fulminant hepatic failure secondary to hydroxychloroquine. Gut 35: 569570.
    [Google Scholar]
  28. Abdel Galil SM, 2015. Hydroxychloroquine-induced toxic hepatitis in a patient with systemic lupus erythematosus: a case report. Lupus 24: 638640.
    [Google Scholar]
  29. Galvañ VG, Oltra MR, Rueda D, Esteban MJ, Redón J, 2007. Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connective tissue disease. Clin Rheumatol 26: 971972.
    [Google Scholar]
  30. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y, 2012. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 42: 145153.
    [Google Scholar]
  31. Jamshidzadeh A et al., 2016. Antimalarial drugs-induced hepatic injury in rats and the protective role of carnosine. Pharm Sci 22: 170180.
    [Google Scholar]
  32. Niknahad H, Heidari R, Firuzi R, Abazari F, Ramezani M, Azarpina N, Niknahad H, Najibi A, Saeedi A, 2016. Concurrent inflammation augments antimalarial drugs-induced liver injury in rats. Adv Pharm Bull 6: 617625.
    [Google Scholar]
  33. Rismanbaf A, Zarei S, 2020. Liver and kidney injuries in COVID-19 and their effects on drug therapy; a letter to editor. Arch Acad Emerg Med 8: e17.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.20-0276
Loading
/content/journals/10.4269/ajtmh.20-0276
Loading

Data & Media loading...

  • Received : 11 Apr 2020
  • Accepted : 13 Apr 2020
  • Published online : 17 Apr 2020
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error